Logan Coy Related postsA Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer After Prior ChemotherapySeptember 11, 2026A Randomized, Multi-Center, Double-Blinded, Placebo-Controlled Trial of XEMBIFY plus Standard Medical Treatment vs Placebo to Prevent Infections in Hypogammaglobulinemia with CLL, Multiple Myeloma, and Non-Hodgkin LymphomaSeptember 11, 2026A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Advanced Solid TumorsSeptember 11, 2026 Previous postAn Open-Label, Multicenter, Phase 1b/2 Study of KRT-232 Combined with Ruxolitinib in Primary Myelofibrosis, Post-PV-MF, or Post-ET-MF with Suboptimal Response to RuxolitinibNext postA Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Mature B-Cell Malignancies